| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 降低合成吖嗪反应器中的二氧化碳含量的方法 | CN92104651.0 | 1992-06-12 | CN1067648A | 1993-01-06 | G·克伦普夫; B·科利耶; P·泰利耶; J·-P·希尔曼 |
| 本发明涉及一种通过将氨、双氧水和带一个羧基的反应物与含有使反应物转化成吖嗪的催化剂的工作溶液相接触合成吖嗪的方法，其特征在于在无CO2的存在下进行操作。 | ||||||
| 2 | 降低合成吖嗪反应器中的二氧化碳含量的方法 | CN92104651.0 | 1992-06-12 | CN1028520C | 1995-05-24 | G·克伦普夫; B·科利耶; P·泰利耶; J·P·希尔曼 |
| 本发明涉及一种通过将氨、双氧水和带一个羰基的反应物与含有使反应物转化成吖嗪的催化剂的工作溶液相接触合成吖嗪的方法，其特征在于在无CO2的存在下进行操作。 | ||||||
| 3 | ASYMMETRIC SYNTHESIS FOR PREPARING FLUOROLEUCINE ALKYL ESTERS | EP13767554 | 2013-03-25 | EP2831023A4 | 2015-11-18 | HUMPHREY GUY; CHUNG CHEOL K; RIVERA NELO R; BELYK KEVIN |
| 4 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | US14871285 | 2015-09-30 | US09962382B2 | 2018-05-08 | Hariprasad Vankayalapati; Rajendra P. Appalaneni; Y. Venkata Krishna Reddy |
| Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3,4-b] pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo [3,4-b] pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds. | ||||||
| 5 | Process for the Preparation of Fluorinated Diazoalkanes | US15795994 | 2017-10-27 | US20180118664A1 | 2018-05-03 | Rene Königs; Katharina Julia Hock; Lucas Mertens |
| The disclosure relates to a process for preparing a fluorinated diazoalkane in which the process is a continuous process and a β,β-difluoroalkylamine is reacted with an organic nitrite in a reactor, and in which the β,β-difluoroalkylamine and the organic nitrite are initially charged in separate vessels, and also to the use of the process for preparing a fluoroalkyl-substituted compound. | ||||||
| 6 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | US14290125 | 2014-05-29 | US09187473B2 | 2015-11-17 | Hariprasad Vankayalapati; Rajendra P. Appalaneni; Y. Venkata Krishna Reddy |
| Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds. | ||||||
| 7 | ATROPISOMERIC 1,8-BISPHENOLNAPTHALENES AND THEIR USE IN ENANTIOSELECTIVE RECOGNITION AND ASYMMETRIC SYNTHESIS | US14009572 | 2012-04-03 | US20140128637A1 | 2014-05-08 | Christian Wolf; Marwan W. Ghosn |
| This invention related to atropisomeric 1,8-bisphenolnaphthalenes and derivatives thereof of the general formula (I): which are useful in resolution of enantiomers, enantioselective recognition and asymmetric synthesis. | ||||||
| 8 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | US14871278 | 2015-09-30 | US09669028B2 | 2017-06-06 | Hariprasad Vankayalapati; Rajendra P. Appalaneni; Y. Venkata Krishna Reddy |
| Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds. | ||||||
| 9 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | US14871278 | 2015-09-30 | US20160060261A1 | 2016-03-03 | Hariprasad Vankayalapati; Rajendra P. Appalaneni; Y. Venkata Krishna Reddy |
| Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds. | ||||||
| 10 | ASYMMETRIC SYNTHESIS FOR PREPARING FLUOROLEUCINE ALKYL ESTERS | US14387897 | 2013-03-25 | US20150080598A1 | 2015-03-19 | Guy Humphrey; Cheol Chung; Nelo Rivera; Kevin Belyk |
| The instant invention describes a novel asymmetric synthesis of fluoroleucine alkyl esters which utilizes a phase transfer catalyst and a solid additive. | ||||||
| 11 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | US13435327 | 2012-03-30 | US20130102586A1 | 2013-04-25 | Hariprasad Vankayalapati; Rajendra P. Appalaneni; Y. Venkata Krishna Reddy |
| Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds. | ||||||
| 12 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | US14871285 | 2015-09-30 | US20160074395A1 | 2016-03-17 | Hariprasad Vankayalapati; Rajendra P. Appalaneni; Y. Venkata Krishna Reddy |
| Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3, 4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds. | ||||||
| 13 | Atropisomeric 1,8-bisphenolnapthalenes and their use in enantioselective recognition and asymmetric synthesis | US14009572 | 2012-04-03 | US09085511B2 | 2015-07-21 | Christian Wolf; Marwan Ghosn |
| This invention related to atropisomeric 1,8-bisphenolnaphthalenes and derivatives thereof of the general formula (I): which are useful in resolution of enantiomers, enantioselective recognition and asymmetric synthesis. | ||||||
| 14 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | US14290125 | 2014-05-29 | US20140309211A1 | 2014-10-16 | Hariprasad Vankayalapati; Rajendra P. Appalaneni; Y. Venkata Krishna Reddy |
| Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds. | ||||||
| 15 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | US13435327 | 2012-03-30 | US08791112B2 | 2014-07-29 | Hariprasad Vankayalapati; Rajendra P Appalaneni; Y. Vekata Krishna Reddy |
| Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds. | ||||||
| 16 | Continuous production of azines/hydrazine hydrate | US08217752 | 1994-03-25 | US06605265B1 | 2003-08-12 | Jean-Pierre Schirmann; Jean-Pierre Pleuvry; Pierre Tellier |
| Azines, e.g., ketazines, are continuously produced by (i) establishing a loop having an azine reaction medium circulating therein, such loop including an azine reaction zone, means for separating azine final product from the circulating reaction medium, means for heating the reaction medium and for purging water therefrom, and means for recycling heated and purged reaction medium to the azine reaction zone, (ii) introducing hydrogen peroxide, ammonia and a carbonyl compound into the circulating reaction medium in the azine reaction zone, (iii) withdrawing azine final product thus formed from the circulating reaction medium. downstream of the azine reaction zone, (iii) thereafter purging water from the circulating reaction medium to maintain the volume thereof essentially constant, (iv) heating the circulating reaction medium to a temperature of at least 130° C., (v) recycling thus heated reaction medium to the azine reaction zone, and (vi), at any point along the loop, introducing a reagent into the circulating reaction medium as to essentially maintain the equilibrium of the azine-forming reaction; the final product azines are conveniently hydrolyzed into hydrazine hydrate. | ||||||
| 17 | Azine synthesis in the absence of CO.sub.2 | US897830 | 1992-06-12 | US5252309A | 1993-10-12 | Gerard Krempf; Bertrand Collier; Pierre Tellier; Jean-Pierre Schirmann |
| Azines, well suited for hydrolysis into hydrazine, are prepared in high yields by reacting ammonia, aqueous hydrogen peroxide and a carbonyl compound reactant in the presence of a catalytically effective amount of a catalyst medium therefor, i.e., an aqueous solution of ammonium acetate and acetamide or of acetamide and acetic acid, but in the absence of CO.sub.2. | ||||||
| 18 | And the method for the synthesis of azine, Application to hydrazine manufacturing | JP34507589 | 1989-12-29 | JP2650144B2 | 1997-09-03 | JANNPIEERU SHIRUMAN; JANNPIEERU PURURII; PIEERU TERIE |
| 19 | Synthesis of azine and its application to production of hydrazine | JP34507589 | 1989-12-29 | JPH02311448A | 1990-12-27 | JIYANNPIEERU SHIRUMAN; JIYANNPIEERU PURUBURII; PIEERU TERIE |
| PURPOSE: To continuously and stably produce azine by reacting hydrogen peroxide, ammonia and a compd. having a carbonyl group while bringing them into contact with a circulating operation liquid and subsequently successively separating azine and reaction water from the circulating operation liquid. CONSTITUTION: In a reaction apparatus 20, hydrogen peroxide 3, ammonia 4 and a compd. having a carbonyl group (e.g.; acetone, methyl ethyl ketone) 1 are brought into contact with an operation liquid 5 to be reacted at 30-70°C. Azine and an excessive amt. of the compd. having the carbonyl group are separated from the operation liquid and azine is hydrolyzed 60 to obtain hydrolyzed hydrazine 8 and the reaction product and an excessive amt. of the compd. having the carbonyl group recovered after hydrolysis are circulated 1 to the reaction apparatus 20. The operation liquid 9 is sent to a tower 40 and reaction water and a small amt. of ammonia are removed 10 and a tower bottom component is sent to an ion exchange resin absorbing apparatus 50 to remove heavy impurities to be circulated to the reaction apparatus 20. The operation liquid is prepared by forming org. or inorg. oxygen acid, its ammonium salt or its deriv. into a soln. COPYRIGHT: (C)1990,JPO | ||||||
| 20 | How to reduce the amount of carbon dioxide in the azine synthesis reactor | JP17474592 | 1992-06-09 | JPH0780829B2 | 1995-08-30 | クランプ ジェラール; シールマン ジャン−ピエール; テリエ ピエール; コリエ ベルトラン |
QQ群二维码
意见反馈
意见反馈